2026-526016-36-00招募中4 期
A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- UZ Leuven
- 入组人数
- 96
- 试验地点
- 2
研究概览
简要总结
To identify for whom semaglutide works best.
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
- •At least 18 years of age and under 65 years of age at the time of signing the informed consent form (ICF)
- •Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.
- •BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbidity
排除标准
- •Any form of diabetes mellitus (T1- or T2DM), defined as current hemoglobin A1c (HbA1c) > 6.5% or the use of antihyperglycemic drugs (metformin is permitted if prescribed for an indication other than T2DM and at a stable dose for at least 3 months days prior to screening)
- •Acute suicidality or history of suicide attempt within 5 years prior to screening
- •Any condition or major illness which, in the investigator’s opinion, may jeopardise participant safety or compliance with the protocol
- •Unable to understand the risks, realistic benefits and compliance requirements of each program
- •Unwillingness to be informed about incidental findings that may be important for the participant’s health
- •Recent participation (< 30 days) or simultaneous participation in an interventional Trial with an investigational medicinal product (IMP) or device
- •If applicable: Female who is pregnant, breast-feeding or intends to become pregnant in the following 6 months or is of childbearing potential and not using an adequate, highly effective contraceptive
- •For PET scanning (subset n=64): exposure to a significant amount (> 1mSv) of ionizing radiation in other research studies within the last 12 months
- •For MRI scanning: any condition that would interfere with MRI scanning (e.g., cochlear implant, metal fragments in the eyes, cardiac pacemaker, neural stimulator and metallic body inclusion or other metallic implants in the body which may interfere with MRI scanning)
- •Claustrophobia or too much uneasiness in limited spaces (to tolerate confinement during scanning procedures)
- •Severe back problems, interfering with lying in supine position in the scanner without movement for long durations
- •Use of incretin-based drugs, including GLP-1RAs (including dual agonists) and dipeptidyl peptidase-4 (DPP-4) inhibitors or amylin analogues within 3 months prior to screening
- •Contraindications for semaglutide: history of pancreatitis, medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)
- •Chronic kidney disease 3b or worse, defined as estimated Glomerular Filtration Rate (eGFR) < 45 ml/min/1.73m²
- •Previous bariatric surgery
- •Disorders known to affect DA signaling significantly, including movement disorders such as Parkinson’s disease, prolactinoma, paraganglioma, pheochromocytoma.
- •Active use of medication affecting DA signaling, including antiparkinson medications, attention deficit hyperactivity disorder (ADHD) medications, antipsychotics, naltrexone-bupropion for weight management or antidepressants; use of serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or trazodone is permitted if participants are on a stable dose for at least three months. Incidental use of antiemetics or sedative hypnotics is allowed but not within 48 hours prior to a study visit.
- •Current or recent (within the past 6 months) clinically significant alcohol or drug misuse (excluding nicotine) that, in the investigator’s judgment, may compromise participant safety or the integrity of study data.
- •Active severe neuropsychiatric disorders, including dementia, psychotic disorder, bipolar disorder and severe depression
研究组 & 干预措施
Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen
Test
干预措施: Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen (Drug)
研究者
Roman Vangoitsenhoven
Scientific
UZ Leuven
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type2023-506919-18-00Novo Nordisk A/S873
招募中
3 期
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)2023-506918-45-00Novo Nordisk A/S798
招募中
3 期
A research study looking at the effect of semaglutide on the immune system and other biological processes in people with Alzheimer's disease2023-506825-13-00Novo Nordisk A/S13
招募中
不适用
Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated HemoglobinDiabetes MellitusNCT07621419Hospital Italiano de Buenos Aires145
已完成
2 期
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart ValvesHeart FailureNCT07610174Kafrelsheikh University160